Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.

Chad MoretzAshley L ColeGeorge MuBenjamin WuAmy GuisingerYunhao LiuBeth HahnLee Baylis

Published in: International journal of chronic obstructive pulmonary disease (2020)

Among non-exacerbating patients with COPD initiating dual therapy, UMEC/VI demonstrated improved adherence and reduced rescue medication use compared with B/F.

Keyphrases

chronic obstructive pulmonary disease
lung function
stem cells
metabolic syndrome
skeletal muscle
replacement therapy